Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost

Chun Nan Kuo, Yu Ming Liao, Li Na Kuo, Hui Ju Tsai, Wei Chiao Chang, Yun Yen

研究成果: 雜誌貢獻回顧型文獻

摘要

Cancer is the leading cause of death in Taiwan, and the overall incidence rate has gradually increased. The four most common cancers in Taiwan are colorectal, lung, breast and liver cancers. With the rise in incidence, the clinical use and costs of all anticancer drugs have steadily increased. The costs of novel therapeutics, such as targeted therapies and immunotherapy were accounted almost two-third of all antineoplastic agents in Taiwan. Moving forward, it will be necessary to discuss the economic impacts to clinical use of new therapeutics, while continuing to monitor and improve the quality of cancer therapy. In this review, we describe the epidemiology, disease screening policies and medication treatment policies for colorectal, lung, breast and liver cancer. We focus on the recent developments in cancer therapeutics, discuss the use of biomarkers, and finally consider the costs and the recent advances of anticancer medications in Taiwan.

原文英語
期刊Journal of the Formosan Medical Association
DOIs
出版狀態接受/付印 - 一月 1 2019

指紋

Taiwan
Health Care Costs
Epidemiology
Biomarkers
Therapeutic Uses
Liver Neoplasms
Costs and Cost Analysis
Colorectal Neoplasms
Lung Neoplasms
Neoplasms
Breast Neoplasms
Incidence
Therapeutics
Antineoplastic Agents
Immunotherapy
Cause of Death
Economics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Cancers in Taiwan : Practical insight from epidemiology, treatments, biomarkers, and cost. / Kuo, Chun Nan; Liao, Yu Ming; Kuo, Li Na; Tsai, Hui Ju; Chang, Wei Chiao; Yen, Yun.

於: Journal of the Formosan Medical Association, 01.01.2019.

研究成果: 雜誌貢獻回顧型文獻

@article{0776217a2dfd4793bd1bd6461a211a7f,
title = "Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost",
abstract = "Cancer is the leading cause of death in Taiwan, and the overall incidence rate has gradually increased. The four most common cancers in Taiwan are colorectal, lung, breast and liver cancers. With the rise in incidence, the clinical use and costs of all anticancer drugs have steadily increased. The costs of novel therapeutics, such as targeted therapies and immunotherapy were accounted almost two-third of all antineoplastic agents in Taiwan. Moving forward, it will be necessary to discuss the economic impacts to clinical use of new therapeutics, while continuing to monitor and improve the quality of cancer therapy. In this review, we describe the epidemiology, disease screening policies and medication treatment policies for colorectal, lung, breast and liver cancer. We focus on the recent developments in cancer therapeutics, discuss the use of biomarkers, and finally consider the costs and the recent advances of anticancer medications in Taiwan.",
keywords = "Biomarkers, Cancer, Cost, Taiwan, Treatment",
author = "Kuo, {Chun Nan} and Liao, {Yu Ming} and Kuo, {Li Na} and Tsai, {Hui Ju} and Chang, {Wei Chiao} and Yun Yen",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jfma.2019.08.023",
language = "English",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",

}

TY - JOUR

T1 - Cancers in Taiwan

T2 - Practical insight from epidemiology, treatments, biomarkers, and cost

AU - Kuo, Chun Nan

AU - Liao, Yu Ming

AU - Kuo, Li Na

AU - Tsai, Hui Ju

AU - Chang, Wei Chiao

AU - Yen, Yun

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cancer is the leading cause of death in Taiwan, and the overall incidence rate has gradually increased. The four most common cancers in Taiwan are colorectal, lung, breast and liver cancers. With the rise in incidence, the clinical use and costs of all anticancer drugs have steadily increased. The costs of novel therapeutics, such as targeted therapies and immunotherapy were accounted almost two-third of all antineoplastic agents in Taiwan. Moving forward, it will be necessary to discuss the economic impacts to clinical use of new therapeutics, while continuing to monitor and improve the quality of cancer therapy. In this review, we describe the epidemiology, disease screening policies and medication treatment policies for colorectal, lung, breast and liver cancer. We focus on the recent developments in cancer therapeutics, discuss the use of biomarkers, and finally consider the costs and the recent advances of anticancer medications in Taiwan.

AB - Cancer is the leading cause of death in Taiwan, and the overall incidence rate has gradually increased. The four most common cancers in Taiwan are colorectal, lung, breast and liver cancers. With the rise in incidence, the clinical use and costs of all anticancer drugs have steadily increased. The costs of novel therapeutics, such as targeted therapies and immunotherapy were accounted almost two-third of all antineoplastic agents in Taiwan. Moving forward, it will be necessary to discuss the economic impacts to clinical use of new therapeutics, while continuing to monitor and improve the quality of cancer therapy. In this review, we describe the epidemiology, disease screening policies and medication treatment policies for colorectal, lung, breast and liver cancer. We focus on the recent developments in cancer therapeutics, discuss the use of biomarkers, and finally consider the costs and the recent advances of anticancer medications in Taiwan.

KW - Biomarkers

KW - Cancer

KW - Cost

KW - Taiwan

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85072047311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072047311&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2019.08.023

DO - 10.1016/j.jfma.2019.08.023

M3 - Review article

AN - SCOPUS:85072047311

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

ER -